Delta 9 Cannabis (TSXV:NINE) released its financial report for the second quarter of its fiscal 2018, which ended on June 30.

As quoted in the press release:


Highlights

  • Revenues of C$715,746 and C$1,047,853 – up 277 percent and 210 percent respectively – for the 3 month and 6 month period ending June 30, 2018 versus the same period in the prior year
  • Gross Profit of C$663,440 and C$866,135 – up 172 percent and 215 percent respectively – for the 3 month and 6 month period ending June 30, 2018, versus the same period in the prior year
  • The Company made a C$3,000,000 Investment to acquire 50 per cent of the 70,000 square foot Delta West cannabis production facility in Calgary, Alberta, which it operates in partnership with Westleaf Cannabis, primarily to supply the cannabis market in Alberta
  • The Company signed a 2,300 [kilograms] supply agreement with the Manitoba Provincial Government
  • The Company came to terms on a C$12,000,000 credit facility with a Tier 1 Canadian chartered bank, providing Delta 9 with additional capital for operations and expansion. The closing of such credit facility remains subject to due diligence
  • The Company signed a Memorandum of Understanding with US biotech firm Nanosphere Health Sciences ceding the Master License in Canada for Nanosphere’s patented delivery system for cannabis
  • The Company is currently completing work necessary to acquire the European Union “Good Manufacturing Practices” (GMP) Certification in order to initiate exports of medical cannabis to Germany
  • The Company executed its option to acquire the land on which its current facility is located, as well as neighbouring property, giving Delta 9 the capacity to expand to more than 2 million square feet

Click here to read the full press release.

Source: www.newswire.ca

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less